Cenobamate

CAS No. 913088-80-9

Cenobamate( YKP-3089 | YKP3089 )

Catalog No. M16559 CAS No. 913088-80-9

Cenobamate (YKP-3089, YKP3089) is a potential anti-seizure agent with currently unknown mechanisms of action.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Cenobamate
  • Note
    Research use only, not for human use.
  • Brief Description
    Cenobamate (YKP-3089, YKP3089) is a potential anti-seizure agent with currently unknown mechanisms of action.
  • Description
    Cenobamate (YKP-3089, YKP3089) is a potential anti-seizure agent with currently unknown mechanisms of action.Epilepsy Phase 3 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    YKP-3089 | YKP3089
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Other Targets
  • Research Area
    Neurological Disease
  • Indication
    Epilepsy

Chemical Information

  • CAS Number
    913088-80-9
  • Formula Weight
    267.67
  • Molecular Formula
    C10H10ClN5O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    NC(O[C@H](C1=CC=CC=C1Cl)CN2N=CN=N2)=O
  • Chemical Name
    (R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl carbamate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zaccara G, et al. Pharmacol Res. 2016 Feb;104:38-48.
molnova catalog
related products
  • N-Sulfo-glucosamine ...

    N-Sulfo-glucosamine sodium salt is possible to effect reaction at arthritis.

  • Galanin (1-16), mous...

    Galanin(1-16),mouse,porcine,rat(TFA) is a Galanin receptor agonist with a Kd value of 3nM.

  • C-Reactive Protein (...

    CRP, an acute phase serum protein synthesized in response to inflammatory cytokines, produces antitumor effects in animals. The fragment CRP (174-185) (RS-83277) shows similar activity by significantly enhancing the tumoricidal activity of human monocytes and alveolar macrophages in vitro.